JP2023540618A5 - - Google Patents
Info
- Publication number
- JP2023540618A5 JP2023540618A5 JP2023516079A JP2023516079A JP2023540618A5 JP 2023540618 A5 JP2023540618 A5 JP 2023540618A5 JP 2023516079 A JP2023516079 A JP 2023516079A JP 2023516079 A JP2023516079 A JP 2023516079A JP 2023540618 A5 JP2023540618 A5 JP 2023540618A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077233P | 2020-09-11 | 2020-09-11 | |
| US63/077,233 | 2020-09-11 | ||
| PCT/EP2021/075012 WO2022053652A1 (en) | 2020-09-11 | 2021-09-10 | Combination therapy for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540618A JP2023540618A (ja) | 2023-09-25 |
| JP2023540618A5 true JP2023540618A5 (https=) | 2024-09-17 |
| JPWO2022053652A5 JPWO2022053652A5 (https=) | 2024-09-17 |
Family
ID=78073883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516079A Pending JP2023540618A (ja) | 2020-09-11 | 2021-09-10 | 癌の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364230A1 (https=) |
| EP (1) | EP4211168A1 (https=) |
| JP (1) | JP2023540618A (https=) |
| KR (1) | KR20230066586A (https=) |
| CN (1) | CN116601171A (https=) |
| AU (1) | AU2021339005A1 (https=) |
| CA (1) | CA3191282A1 (https=) |
| IL (1) | IL301048A (https=) |
| MX (1) | MX2023002852A (https=) |
| WO (1) | WO2022053652A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026022712A1 (en) * | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101615935B1 (ko) | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2020033630A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
-
2021
- 2021-09-10 WO PCT/EP2021/075012 patent/WO2022053652A1/en not_active Ceased
- 2021-09-10 CA CA3191282A patent/CA3191282A1/en active Pending
- 2021-09-10 MX MX2023002852A patent/MX2023002852A/es unknown
- 2021-09-10 US US18/044,730 patent/US20230364230A1/en active Pending
- 2021-09-10 JP JP2023516079A patent/JP2023540618A/ja active Pending
- 2021-09-10 EP EP21786092.3A patent/EP4211168A1/en active Pending
- 2021-09-10 IL IL301048A patent/IL301048A/en unknown
- 2021-09-10 KR KR1020237011801A patent/KR20230066586A/ko active Pending
- 2021-09-10 AU AU2021339005A patent/AU2021339005A1/en not_active Abandoned
- 2021-09-10 CN CN202180062423.4A patent/CN116601171A/zh active Pending